Easan 150 mg Powder for solution for infusion
PDF Leaflet Revision Date: 7 March 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of nausea and vomiting associated with cancer chemotherapy.
Dosage (summary)
150 mg IV on Day 1, no adjustment for elderly or renal impairment.
Onset of Action / Duration
Onset: 30 mins, Duration: Not specified.
Special Populations
- Moderate hepatic impairment
- Severe hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; breastfeeding not advised.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Warfarin
Contraindications
- Hypersensitivity to aprepitant
- Co-administration with pimozide
- Pregnancy
- Breastfeeding
- Paediatric patients
Common side effects
- Fatigue
- Headache
- Constipation
- Dyspepsia
- Hiccups
Counselling Points
- Monitor for hypersensitivity
- Use non-hormonal contraception
- Avoid in pregnancy and breastfeeding
Serious warnings
- Hypersensitivity reactions
- Infusion site reactions
- Caution in hepatic impairment
Important Disclaimer
The Easan 150 mg Powder for solution for infusion professional information leaflet below is the property of Kahma Biotech and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
